This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Falorni, A. Articles by Calcinaro, F. Search for Related Content PubMed PubMed Citation Articles by Falorni, A. Articles by Calcinaro, F.

Autoantibody Recognition of COOH-Terminal Epitopes of GAD65 Marks the Risk for Insulin Requirement in Adult-Onset Diabetes Mellitus¹

Department of Internal Medicine and Endocrine and Metabolic Sciences, University of Perugia, Perugia, Italy

Address correspondence and requests for reprints to: Alberto Falorni, M.D., Ph.D., Department of Internal Medicine and Endocrine & Metabolic Sciences, Via E. Dal Pozzo, 06126 Perugia, Italy. E-mail: falorni{at}dimisem.med.unipg.it

Some type 2 diabetic subjects develop secondary failure to sulphonylurea treatment and require insulin therapy. To test the diagnostic sensitivity and specificity of epitopes of GAD65 autoantibodies (GAD65Ab) for insulin requirement, in patients with latent autoimmune diabetes of the adult, we studied 569 adult subjects with a clinical diagnosis of type 2 diabetes mellitus. All the patients had been initially treated with hypoglycemic agents and/or diet for at least 1 yr. The presence of GAD65Ab (61/569, 10.7%) depended on insulin therapy (P < 0.0001), low BMI (P < 0.0001), and low basal C-peptide (P = 0.01). The majority of GAD65Ab-positive subjects (47/61, 77%) had antibodies directed to both middle (GAD65-MAb) and COOH-terminal (GAD65-CAb) epitopes. However, GAD65-CAb were more frequent in insulin-treated subjects (92% of GAD65Ab+ individuals) than in subjects treated with hypoglycemic agents and/or diet (18.2% of GAD65Ab+ individuals), while the exclusive presence of GAD65-MAb was more frequent in subjects treated with hypoglycemic agents and/or diet (81.8% vs. 8%) (P < 0.0001). The presence of GAD65-CAb had a diagnostic specificity for insulin requirement as high as 99.4% (compared with 96.9% of GAD65Ab as measured in the traditional radiobinding assay) and identified a subgroup of patients with low BMI, low basal C-peptide values, and a need for insulin therapy. Subjects carrying only GAD65-MAb were phenotypically indistinguishable from GAD65Ab-negative patients. Patients positive for GAD65-M+CAb, but not those positive for GAD65-MAb only, showed an increased risk for thyroid autoimmunity, as revealed by the presence of thyroid peroxidase autoantibodies. Our study demonstrates that the use of epitope-specific antibody assays improves the diagnostic specificity of GAD65Ab, and that the presence of GAD65Ab binding to COOH-terminal epitopes is strongly associated with a need for insulin requirement.

This article has been cited by other articles:

				C. Tiberti, C. Giordano, M. Locatelli, E. Bosi, G. F. Bottazzo, R. Buzzetti, D. Cucinotta, A. Galluzzo, A. Falorni, and F. Dotta Identification of Tyrosine Phosphatase 2(256-760) Construct as a New, Sensitive Marker for the Detection of Islet Autoimmunity in Type 2 Diabetic Patients: The Non-Insulin Requiring Autoimmune Diabetes (NIRAD) Study 2 Diabetes, May 1, 2008; 57(5): 1276 - 1283. [Abstract] [Full Text] [PDF]

				K. L. Jones Role of Obesity in Complicating and Confusing the Diagnosis and Treatment of Diabetes in Children Pediatrics, February 1, 2008; 121(2): 361 - 368. [Abstract] [Full Text] [PDF]

				P. Candeloro, C. B. Voltattorni, R. Perniola, M. Bertoldi, C. Betterle, M. Mannelli, R. Giordano, A. De Bellis, C. Tiberti, S. Laureti, et al. Mapping of Human Autoantibody Epitopes on Aromatic L-Amino Acid Decarboxylase J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1096 - 1105. [Abstract] [Full Text] [PDF]

				S Genovese, E Bazzigaluppi, D Goncalves, A Ciucci, M G Cavallo, F Purrello, M Anello, C M Rotella, G Bardini, O Vaccaro, et al. Clinical phenotype and {beta}-cell autoimmunity in Italian patients with adult-onset diabetes. Eur. J. Endocrinol., March 1, 2006; 154(3): 441 - 447. [Abstract] [Full Text] [PDF]

				C. Pihoker, L. K. Gilliam, C. S. Hampe, and A. Lernmark Autoantibodies in Diabetes Diabetes, December 1, 2005; 54(suppl_2): S52 - S61. [Abstract] [Full Text] [PDF]

				J. P. Palmer, C. S. Hampe, H. Chiu, A. Goel, and B. M. Brooks-Worrell Is Latent Autoimmune Diabetes in Adults Distinct From Type 1 Diabetes or Just Type 1 Diabetes at an Older Age? Diabetes, December 1, 2005; 54(suppl_2): S62 - S67. [Abstract] [Full Text] [PDF]

				M. Maioli, E. Alejandro, G. Tonolo, L. K. Gilliam, L. Bekris, C. S. Hampe, D. A. Obinu, A. Manconi, L. Puddu, K. Lynch, et al. Epitope-Restricted 65-Kilodalton Glutamic Acid Decarboxylase Autoantibodies among New-Onset Sardinian Type 2 Diabetes Patients Define Phenotypes of Autoimmune Diabetes J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5675 - 5682. [Abstract] [Full Text] [PDF]

				P. Achenbach, K. Warncke, J. Reiter, H. E. Naserke, A. J.K. Williams, P. J. Bingley, E. Bonifacio, and A.-G. Ziegler Stratification of Type 1 Diabetes Risk on the Basis of Islet Autoantibody Characteristics Diabetes, February 1, 2004; 53(2): 384 - 392. [Abstract] [Full Text] [PDF]

				J. P. Palmer, G. A. Fleming, C. J. Greenbaum, K. C. Herold, L. D. Jansa, H. Kolb, J. M. Lachin, K. S. Polonsky, P. Pozzilli, J. S. Skyler, et al. C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve {beta}-Cell Function: Report of an ADA Workshop, 21-22 October 2001 Diabetes, January 1, 2004; 53(1): 250 - 264. [Abstract] [Full Text] [PDF]

				C. J. Padoa, J. P. Banga, A.-M. Madec, M. Ziegler, M. Schlosser, E. Ortqvist, I. Kockum, J. Palmer, O. Rolandsson, K. A. Binder, et al. Recombinant Fabs of Human Monoclonal Antibodies Specific to the Middle Epitope of GAD65 Inhibit Type 1 Diabetes-Specific GAD65Abs Diabetes, November 1, 2003; 52(11): 2689 - 2695. [Abstract] [Full Text] [PDF]

				T. Kobayashi, S. Tanaka, M. Okubo, K. Nakanishi, T. Murase, and A. Lernmark Unique Epitopes of Glutamic Acid Decarboxylase Autoantibodies in Slowly Progressive Type 1 Diabetes J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4768 - 4775. [Abstract] [Full Text] [PDF]

				W. E. Winter, N. Harris, and D. Schatz Immunological Markers in the Diagnosis and Prediction of Autoimmune Type 1a Diabetes Clin. Diabetes, October 1, 2002; 20(4): 183 - 191. [Abstract] [Full Text] [PDF]

				B. Szepietowska, M. Szelachowska, and I. Kinalska Do Latent Autoimmune Diabetes of the Adult (LADA) Patients Require Insulin at Diagnosis?: Response to Pozzilli and Di Mario Diabetes Care, September 1, 2002; 25(9): 1662 - 1663. [Full Text]

				G. Gambelunghe, M. Ghaderi, C. Tortoioli, A. Falorni, F. Santeusanio, P. Brunetti, C. B. Sanjeevi, and A. Falorni Two Distinct MICA Gene Markers Discriminate Major Autoimmune Diabetes Types J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3754 - 3760. [Abstract] [Full Text] [PDF]

				D. B. Sacks and A. Lernmark Molecular Manipulation of Autoantibody Testing in Type 1 Diabetes: Two for One Clin. Chem., May 1, 2001; 47(5): 803 - 804. [Full Text] [PDF]